The many faces of microbiota-gut-brain axis in autism spectrum disorder.

Autor: Gonçalves CL; Graduate Program in Health Sciences, University of Southern Santa Catarina (UNESC), Criciúma, SC, Brazil. Electronic address: cinaralg@unesc.net., Doifode T; Louis A. Faillace, MD, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health (UTHealth), Houston, TX, USA., Rezende VL; Graduate Program in Health Sciences, University of Southern Santa Catarina (UNESC), Criciúma, SC, Brazil., Costa MA; Graduate Program in Health Sciences, University of Southern Santa Catarina (UNESC), Criciúma, SC, Brazil., Rhoads JM; Department of Pediatrics, Division of Pediatric Gastroenterology, McGovern Medical School, The University of Texas Health (UTHealth), Houston, TX, USA., Soutullo CA; Louis A. Faillace, MD, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health (UTHealth), Houston, TX, USA.
Jazyk: angličtina
Zdroj: Life sciences [Life Sci] 2024 Jan 15; Vol. 337, pp. 122357. Date of Electronic Publication: 2023 Dec 19.
DOI: 10.1016/j.lfs.2023.122357
Abstrakt: The gut-brain axis is gaining more attention in neurodevelopmental disorders, especially autism spectrum disorder (ASD). Many factors can influence microbiota in early life, including host genetics and perinatal events (infections, mode of birth/delivery, medications, nutritional supply, and environmental stressors). The gut microbiome can influence blood-brain barrier (BBB) permeability, drug bioavailability, and social behaviors. Developing microbiota-based interventions such as probiotics, gastrointestinal (GI) microbiota transplantation, or metabolite supplementation may offer an exciting approach to treating ASD. This review highlights that RNA sequencing, metabolomics, and transcriptomics data are needed to understand how microbial modulators can influence ASD pathophysiology. Due to the substantial clinical heterogeneity of ASD, medical caretakers may be unlikely to develop a broad and effective general gut microbiota modulator. However, dietary modulation followed by administration of microbiota modulators is a promising option for treating ASD-related behavioral and gastrointestinal symptoms. Future work should focus on the accuracy of biomarker tests and developing specific psychobiotic agents tailored towards the gut microbiota seen in ASD patients, which may include developing individualized treatment options.
Competing Interests: Declaration of competing interest Cinara L. Gonçalves, Tejaswini Doifodeb, Victoria L. de Rezende, Maiara A. da Costa have no declarations of interest. J. Marc Rhoads, MD has funding from the National Institutes of Health R01AT007083 and DK056338 and BioGaia AB. Cesar A. Soutullo MD, PhD (2019–2023): Full Time: Professor of Psychiatry. UT Health Science Center at Houston, TX, USA. Research funds (Departamental, non-personal): Texas Child Mental Health Care Consortium (Youth Depression & Suicide Network) SB11, the Vivian L. Smith Foundation, The Fravrot Fund and John S. Dunn Foundation Consultant/Advisory Board: EUNETHYDIS (European Network on Hyperkinetic Disorder) (European ADHD Guidelines Group), NeuroTech Solutions Ltd. (International Advisory Board), Limbix Heatlh/Big Health (DSMB), MEDEA (Spain), Innosphere (Germany). Speaker's Bureau (Continuous Medical Education, non-product related): Bial (Portugal), Medice (Germany), Rubiò (Spain), Cuquerella Medical Consulting (Spain), Tecnofarma/Adium (LatinAmerica). Royalties: Editorial Médica Panamericana.
(Copyright © 2023. Published by Elsevier Inc.)
Databáze: MEDLINE
Externí odkaz: